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The detection of foreign viral or minor histocompatibility antigen by cytotoxic
T lymphocytes (CTL) requires the corecognition ofcell surface glycoproteins en-
coded by the class I loci of the MHC (1-4). Recently it was demonstrated (5, 6)
that the expression oftruncated versions of viral genes in transfected cell lines can
render them susceptible to CTL lysis. It was subsequently shown (7-9) that syn-
thetic peptides couldeffectivelysubstitute for foreign antigens during MHC-restricted
CTL-mediated lysis. For example, Townsend et al. (7) showed that a synthetic pep-
tide from the influenzanucleoprotein sequence was effective in sensitizing uninfected
target cells for influenza-specific CTL recognition.
As a consequence ofthese observations, it has been suggested that endogenously
expressed viral antigens may in fact be fragmented by some cellular degradation
mechanism before expression on the surface of the cell in conjunction with MHC
ready for T cell recognition (6, 10, 11). Virtually all cellular proteins, in addition
to viral antigens, could therefore generate relevant peptide fragments that serve as
potential MHC classIligands. While adirect peptide-class I MHC protein interac-
tion has yet to be demonstrated for either foreign or selfantigens, recent crystallo-
graphic data on a human class I glycoprotein are consistent with this idea (12, 13).
Given this view, it is clear that any particular MHC/peptide complex would repre-
sent only a small proportion ofthe total MHC-encoded molecules found on the cell
surface. This type of argument has been presented previously to explain the high
frequency of T cells responding to stimulator cells that express allogeneic MHC
products (alloreactive T cells). On the one hand, it has been proposed that the high
frequency ofT cells responsive to stimulators expressing allogeneic MHC products
results from the enormous multiplicity ofnew peptide/MHC complexes on the sur-
face (14). Alternatively, it has been proposed that alloreactivity may be due to the
fact that some determinants on theallo-MHC molecule will be expressed at a much
higher density than any one self-restricted peptide/MHC determinant (15, 16).
We reasoned that the association ofexogenous, soluble peptides with MHC class
I products during in vitro culture may be more efficient than would be the case for
the comparableendogenously produced determinant. Thisefficient associationwould
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result in adisproportionately high density ofMHC class I protein/peptide complex
on the cell surface. Soluble peptide could then potentially generate a stronger T cell
response than is usually observed for class I-restricted antigens. We show here that
peptide fragments can effectively generate a strong primary in vitro CTL response.
This response is both peptide specific and MHC restricted but clearly differs from
the secondaryCTL response seenafter conventional in vivo immunization with live
virus.
Materials and Methods
Mice.
￿
C57BL/6, B10.A(4R), and B10.A(5R) mice were obtained from theScripps Clinic
and Research Foundation vivarium.
Monoclonal Antibodies.
￿
mAbs used in this study were 13.4 (antiThy-1.2, reference 17),
RL.172 .4 (anti-CD4 (L3T4), reference 18), and 3.168 (anti-CD8 (Lyt-2), reference 19). These
were used with rabbit complement to deplete the appropriate effector cell populations im-
mediately before addition to cytotoxicity assays.
Antigens.
￿
OVA (Grade VI; SigmaChemical Co., St. Louis, MO)wasused in native form
or after cleavage with trypsin (T OVA)' or cyanogen bromide (CN OVA). For T OVA,
100-250 mg of OVA was reduced in 0.2 M 2-ME/8 M urea overnight and then alkylated
with 0.25 M iodoacetic acid for 2 h. The alkylated protein was exhaustively dialyzed and
then cleaved with 1% trypsin in 50 mM NH4CO4, pH 8.0, overnight. For CN OVA, 250
mg of OVA was reacted overnight with 500 mg of CN dissolved in 70% formic acid. The
solvent was evaporated under a stream of nitrogen and the residue was suspended in water
and lyophilized. No intact OVA remained in the CN OVA and T OVA preparations, as as-
sessed by SDS gel electrophoresis. The synthetic peptide antigens NP36s-380 (IASNENMET
MESSTLE) and OVAIII-122 (YPILPEYLQCVK) were synthesized on an automated pep-
tide synthesizer (Applied Biosystems, Inc., Foster City, CA) and their purity was assessed
by HPLC and amino acid analysis.
Influenza VirusStrains.
￿
Influenzavirus stocks ofA/PR/8 andA/HK/68 were obtained from
A. Vitiello, Scripps Clinic and Research Foundation. Virus was grown in the allantoic sacs
of 11-d-old embryonated chicken eggs and stored as infectious allantoic fluid at -70°C.
Target Cellsfor Cytotoxicity Assays.
￿
The tumor cell lines used were the la- lines, EL4
(C57BL/6, H-2b thymoma), P815 (DBA/2, H-2a mastocytoma), CBA-Dl (CBA, H-2k lym-
phoma), and R1.E (TL-) (C58/J, H-2k thymoma). The R1 .E(TL-) line also fails to express
class I MHC gene products on the surface due to a defect in (32-microglobulin expression
(20). EL4 was transfected with OVA cDNA in a plasmid construct with the human 0-actin
promoter to derive the OVA-producing cell line E.G7-OVA, which will be described in detail
elsewhere (Moore, M. W., M. J. Bevan, and R R. Carbone, manuscript in preparation).
Peritoneal exudate cells for use as targets were induced by injecting 1.5 ml of 30 1o wt/vol
thioglycolate (Difco Laboratories Inc., Detroit, MI) intraperitoneally 4 d before harvesting.
PrimaryPeptide-speck CytotoxicEffector Ibpulations.
￿
Unless otherwise stated, 60 x 106 spleen
cells from unprimed 6-8-wk-old C57BL/6 mice were incubated for5din 10 ml of RP10 (RPMI-
1640 with 10% FCS and 50 gM 2-ME) in upright 25-cm' flasks at 37°C in 7olo C02/air.
Concentrations of peptides added to the cultures were 100 wg/ml for CN OVA and T OVA
or 5 jig/ml for NP36s-3ao.
Long-Term CTL Lines.
￿
Primary cytotoxic effector populations were harvested after 7 d,
and 5 x 106 recovered cells were restimulated with 20 x 106 irradiated (3,000 rod) syngeneic
spleen cells in 10 ml of RP10 at the same peptide concentrations as the primary cultures.
Subsequent weekly restimulations were carried out with 2-4 x 106 responder cells and 20
x 106 irradiated syngeneic spleen cells in 10 ml of RP10 with 5% supernatant from Con
A-stimulated rat spleen cells and 50 mM a-methyl mannoside in upright 25-cm2 flasks. Pep-
tides were used at the same concentrations as in primary cultures.
' Abbreviations used in this paper: CN OVA, cyanogen bromide-cleavedovalbumin; T OVA, trypsinized
ovalbumin.CARBONE ET AL.
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CNOVA-speck CTL Clones.
￿
Responder cells recovered from long-term CN OVA-specific
populations were cloned at 10, 3, 1, and 0.3 cells/well in 96-well plates (No. 3596; Costar,
Cambridge, MA). Irradiated syngeneic spleen cells (5 x 105 cells/well) and CN OVA (100
gg/ml) in medium containing 5% supernatant from Con A-stimulated rat spleen cells were
used for cloning. Cells from wells with positive signs ofgrowth (from 3 and 1 cell/well plates)
were expanded and tested for CN OVA-specific lysis. Clones were maintained by weekly re-
stimulation of 1-2 x 105 cells with 5 x 106 irradiated syngeneic cells in 2 ml of CN OVA
containing medium in 24-well plates (No. 3484; Costar).
Generation ofAnti-influenza A/PR/8 CTL.
￿
In vitro secondary anti-A/PR/8 effectors were
derived using responder spleen cells from C57BL/6 mice immunized 4 wk earlier with 100
HAU of A/PR/8 influenza virus intravenously. Stimulator cells were prepared by infecting
108 irradiated (3,000 rad) C57BL/6 cells with 0.5 ml infectious allantoic fluid in 4 ml of
RPMI-1640 for 90 min. Responder cells (25 x 106 cells) and stimulator cells (25 x 106 cells)
were incubated in 20 ml of RP10 medium for 5 d in upright 25-cm2 flasks. Influenza
A/PR/8-reactive cells were selectively expanded from anti-NP365-380 CTL populations after
the third or fourth in vitro stimulation. In this case, 4-6 x 106 responder cells and 20 x
106 A/PR/8-infected irradiated syngeneic spleen cells were incubated for 5 d in 20 ml
medium in upright 25-cm2 flasks.
Cytotoxicity Assay.
￿
For peptide-specific lysis, 106 target cells in 600 ul of RP10 were labeled
with 300 pCi sodium [5'Cr]chromate for 45 min. For influenza-specific lysis, 106 target cells
in 600 ul RPMI-1640 were labeled with 300 pCi of "Cr and simultaneously infected with
100 ul of infectious allantoic fluid for 90 min. After washing, 104 labeled targets and serial
dilutions of effector cells were incubated in 200 gl of RP10 with appropriate peptides. Pep-
tide concentrations used in the assays were 100 wg/ml CN OVA and T OVA, or 10 ug/ml
of NP365-38o and OVAL -122 . After a 4-h incubation at 37°C, 100 ul of supernatant was col-
lected and specific lysis was determined as: Percent specific lysis = 100 x [(release by CTL
- spontaneous release)/(maximal release - spontaneous release)]. Spontaneous release in
the absence of CTL was <25% of maximal release by detergent in all experiments.
Results
Induction of Cytotoxic Effectors by Primary In Vitro Stimulation with Peptides.
￿
Both T
OVA and CN OVA were used as a source of peptides of varying lengths to assess
their ability to generate a primary in vitro CTL response. A 5-d incubation of spleen
cells from unimmunized C57BL/6 mice with 100 pg/ml CN OVA generated effectors
that efficiently lysed the syngeneic tumor target EL4 in the presence of CN OVA
(Fig. 1 a). These effector cells caused only a low level of specific target cell lysis in
the presence of T OVA, and no significant enhancement of killing was seen in the
presence of native OVA when compared with EL4 targets alone (Fig. 1 a). Fig. 1
b shows that effectors of reciprocal specificity resulted when T OVA was used as the
in vitro immunogen. A 5-d incubation of spleen cells with native OVA (Fig. 1 c)
failed to generate effectors capable of lysing targets in the presence of T OVA, CN
OVA, or native OVA.
Synthetic peptides can substitute for endogenously synthesized viral proteins during
CTL recognition (7-9). We attempted to raise CTL by primary in vitro stimulation
using one such peptide, NP365-380, which corresponds to the fragment between
residues 365 and 380 from the influenza virus A/PR/8 nucleoprotein (21). Fig. 1
d shows that incubating spleen cells from unprimed C57BL/6 mice with NP365-380
generated effectors capable of lysing EL4 targets only in the presence of this syn-
thetic peptide and eliminated the possibility that the primary in vitro antipeptide
activity was due to an artifact peculiar to the OVA protein.
Effect of Cell Density on the Primary Response.
￿
During the course of our studies we1770
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FIGURE 1 .
￿
The ability of peptides to elicit
specificCTL after primary in vitro stimula-
tion . Spleen cells from unprimed C57BL/6
mice (60 x 106 cells per flask) were incubated
for 5 d in the presence of 100 t<g/ml (a) CN
OVA, (b) T OVA, (c) native OVA, or (d) 5
wg/ml NP365-380 . The resulting effectors were
then tested for lysis of "Cr-labeled EL4
target cells in the presence of (0100 Pg/ml
CN OVA, (0100 wg/ml T OVA, (")100
ug/ml native OVA, (*)10 wg/ml NP365-380, or
(O) medium alone.
noticed that the most critical parameter affecting the primary in vitro response was
the starting cell density, as demonstrated forCN OVA in Fig . 2 . In this experiment,
starting cell numbers in the range of 40-80 x 106 cells/flask resulted in the stimu-
lation of a strongCN OVA-specific activity, with 20 x 106 cells/flask giving much
weaker activity. Such weak stimulation was generally observed for most attempts
at priming using< 40 x 106 cells/flask . Cell numbers of-60 x 106 were routinely
used for our experiments . All three peptide preparations were capable ofpriming
at this density, with CN OVA giving the best response, followed byTOVA and then
NP365-380
Antipeptide Cytotoxic Effector Cells are Thy-I + andCD8+ Cells.
￿
Peptide-specific lines
were established by repeated antigen stimulationofeffectors generated from the pri-
mary in vitro cultures . To determine whether peptide-specific recognition was in-
deed due to T cell activity, these lines were treated with antiThy-1, anti-CD8 or
anti-CD4 antibodies, and/or complement immediately before theiraddition to assay
cultures . Fig. 3 shows that depletion of CD8+ or Thy-1+ cells from both anti-CN
OVA and anti-NP365-380 lines abrogated all specific lytic activity. Neither comple-
ment alone nor anti-CD4 had any effect . Similarly, all the TOVA activity is sensi-
tive to antiThy-1 andanti-CD8 antibody and complement treatment (datanot shown) .
Effectors were therefore classical CD8+ T cells .
OVA111-122 Is a Target PeptideforAnti-TOVA CTL .
￿
Based on the preliminary anal-
ysis ofachromatographic separation of an OVA tryptic digest (not shown), a limitedJ
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number of peptides were synthesized in an attempt to identify the fragments recog-
nized by the OVA digest-specific CTL. Anti-T OVA CTL lines showed strong lysis
of the H-2-compatible target EL4 in the presence of one such peptide, synthetic
tryptic fragment OVAn1-122 (Table I). This peptide did not sensitize targets to the
same extent as the whole T OVA digest, suggesting that OVA111-122 represented a
major but not exclusive determinant for the bulk of antiT OVA CTL. In other ex-
periments we estimated that the activity against this peptide accounted for 10-100 %
of the total CTL activity.
Peptide-speck LysisIs ClassIRestricted.
￿
Thioglycolate-inducedperitoneal exudate
cells from C57L/6 (Kb, Db), B10.A(4R) (Kk, Db), and B10.A(5R) (Kb, Dd) mice
served as convenient targets for mapping the restriction element used by the three
different effector populations. Table II shows that anti-NP365-380 CTL lysed
L
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FIGURE 2.
￿
The effect of cell density on primary in vitro pep-
tide stimulation. Spleen cells from unprimed C57BL/6 mice
(9, 0: 80 x 106 ; /, El : 60 x 106; A, A: 40 x 106; *, 0: 20
x 106 cells) were incubated for 5 d in the presence of 100 Ag/ml
CN OVA. The resulting effectors were then tested for lysis of
51Cr-labeled EL4 target cells in the absence (open symbols) or
presence (closed symbols) of 100 ug/ml CN OVA.
30:110:1 3:1 30:1 10:1 3:1
FIGURE 3.
￿
Peptide-specific effectors are CD8'
T cells. Long-term (a) anti-CN OVA and (b) anti-
NP365-380-specific effector populations were
treated with complement in the presence of(/)
antiThy-1, ( ") anti-CD4, (O) anti-CD8, or (EI)
no antibody before addition to 51Cr-labeled EL4
in the presence of (a) 100 ug/ml CN OVA or (b)
10pg/ml NP365-380.1772
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TABLE I
Peptide Specificity of Anti-T OVA CTL
Specific Lysis in the presence of*
* 5 'Cr-labeled EL4 cells were used as targets for lysis by anti-T OVA CTI.
population derived from primary in vitro stimulation.
$ 100 jig/ml T OVA digest.
3 10 Vg/ml OVAtit-122
C57BL/6 and B10.A(4R) but not B10.A(5R) cells in the presence of NP365-380. Rec-
ognition of the NP365-380 peptide was clearly restricted to the Db locus. This coin-
cides with the fact that NP365-380 CTL derived from virus-infected C57BL/6 mice
are also Db restricted (7, 22). The anti-T OVA CTL response was also predomi-
nantly Db restricted since strong peptide-specific killing was observed for both
C57BL/6 and B10.A(4R) targets (Table II). In this case, weak lysis was apparent
for B10.A(5R) targets in the presence of the T OVA digest, suggesting a minor Kb_
restricted activity.
Anti-CN OVA CTL efficiently recognized all three peritoneal exudate targets in
thepresence ofCN OVA(Table 11). In addition, this line also lysed theclass II-negative
tumor targets P815 (H-2d) and CBA-Dl(H-2 k) in a peptide-specific manner (Fig.
4 a). The C58/J (H-2k)-derived line R1.E (TL- ) is R2-microglobulin-negative, and
accordingly, does not express class I MHC gene products on its surface. The failure
of anti-CN OVA CTL to lyse R1 .E (TL- ) (Fig. 4 a) suggests that anti-CN OVA
CTL are indeed class I restricted despite an unusual crossreaction on at least three
TABLE II
MHC Restriction of Peptide-specific CTL Recognition
* 5'Cr-labeled thioglycolate-induced peritoneal exudate cells from C57BL/6, B10.A(4R), and B10 .A(5R) mice
were used as targets for lysis by CTL populations derived from primary in vitro peptide stimulation .
1 E/T Ratio.
$ 10 4g/ml NP365-380-
100 vg/ml OVA digest.
CTL effector Added peptides
C57BL/6*
10:1 3 :11
Specific lysis
BIO.A(4R)
10:1
of targets
3:1
from:
B10.A(5R)
10 :1 3 :1
anti-NP365-380 NP365-3804 50 29 47 31 - 4 -1
None 0 - 1 - 3 - 3 2 0
anti-T OVA T-OVA, 35 32 30 20 12 7
None - 3 0 8 7 4 5
anti-CN OVA CN-OVA' 64 62 62 52 57 42
None 5 7 8 7 4 0
E/T Medium control T OVAI OVAL 11-122
30:1 9 67 48
15:1 4 47 23
8:1 1 22 10CARBONE ET AL .
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FIGURE 4.
￿
Peptide-specific lysis ofvarious tumor
targets by antipeptide CTL . 5'Cr-release assay
for specific CTL lysis of tumor targets (" , O)
EL4, (A, A) P815, (/, [3) CBA-Dl, and (*,
,0) R1.E(TL- ) in the presence (closed symbols) or
absence (open symbols) of peptides (a) 100 gg/ml
CNOVA for anti-CNOVA effectors and (b) 100
vg/ml T OVA for anti-T OVA effectors.
different H-2 haplotypes . No peptide-specific lysis oftumor targets other than the
class II-negative EL4 was observed for anti-T OVA CTL (Fig . 4 b) and anti-
NP365-380 (data not shown), confirming that these activities show classical class I
MHC restriction .
Individual CN OVA-specific Clones Recognize Peptide in the Context of H-2°, H-2d, and
H-2k . The broad MHC haplotype crossreactivity shown by the anti-CN OVA
populationmayhave been aconsequenceofa more limited recognition by individual
Tcell clones ofdifferent specificities within thewhole population . Forexample, there
may be some clones that recognizeCN OVA in association with H-26 and H-2' but
not H-2d, while others are restricted to H-2b and H-2d . This possibility was ruled
out by examing theanti-CNOVA response at the clonal level. FiveCN OVA-specific
clones were established by limiting dilution from the bulk population used in the
preceding section . All five clones exhibited CN OVA-specific lysis on each of the
threetumor targets (Table III) . Consequently, individual clones could recognize the
TABLE III
Lysis of a Range of Target Cells by CN OVA-speck CTL Clones
* "'Cr-labeled EL4, P815, and CBA-DI tumor cells were used as targets for lysis by CN OVA-specific CTL
clones .
1 E/T ratio .
4 100 wg/ml CN OVA digest .
Target
Added
peptide
C3
10 :1 3:11
Specific
C7
3 :1
lysis
1 :1
of targets
C11
10 :1
by
3 :1
CTL clones :*
-C12
10:1 3 :1 3 :1
C13
1 :1
EL4 CN OVA4 37 24 40 22 47 34 50 41 52 40
None 4 3 3 2 3 0 8 6 15 10
P815 CN OVA 42 30 59 36 68 52 55 57 66 50
None 4 1 6 0 4 0 17 11 28 8
CBA-D1 CN OVA 46 38 78 56 66 57 58 57 62 55
None 2 - 1 14 3 5 4 9 7 10 31774
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F- a0~- were tested for killing on 51Cr
CN
OVA digest on restricting elements encoded by the H-2b, H-2d, and H-2' haplo-
types.
We have not determined whether the peptide is the same for all five clones
nor
have we identified the peptide(s) responsible for target sensitization
.
The
Majority of In Vitro-induced Antipeptide CTL Fail to Lyse Cells that Endogenously
Express
the Foreign Antigen
.
The CTL lines generated from primary in vitro stimula-
tion
were assessed for their ability to lyse targets expressing endogenous forms of
the
appropriate antigens
.
Neither the anti-CN OVA CTL (Fig
.
5 a) nor the anti-T
OVA
CTL (Fig
.
5 b) could lyse the OVA-expressing transfectant E
.G7-OVA.
This
lack
of recognition was not due to defective antigen presentation, since E
.G7-OVA
is
effectively lysed by OVA-specific H-26-restricted CTL derived from mice previ-
ously
immunized with this transfectant (Moore, M
.
W
.,
M
.
J
.
Bevan, and F
.
R
.
Carbone,
manuscript in preparation)
.
Similarly, the anti-NP365-380 line failed to
show
significant lysis of influenza A/PR/8-infected EL4 cells even at high E/T ratios
(Fig.
5 c)
.
The
anti-NP365-380 CTL line used for the experiment shown in Fig
.
5 c was split
and
stimulated for a further 5 d in the presence of either NP365-380 or A/PR/8-
infected
spleen cells
.
The A/PR/8-selected line showed a dramatic increase in lysis
of
A/PR/8-infected EL4 target cells (Fig
.
6 b) when compared with the peptide-
stimulated
line (Fig
.
6 a)
.
The virus-selected anti-NP365-38o line did not recognize
A/HK/68-infected
targets
.
In contrast, A/HK/68-infected EL4 cells were efficiently
recognized
by secondary CTL derived from A/PR/8-infected C57BL/6 mice (Fig
.
6
c)
.
This virus crossreactivity has been attributed to a nucleoprotein-specific sub-
population
within the secondary A/PR/8 response (23, 24)
.
Spleen cells from the
same
batch of unimmunized C57BL/6 mice used to set up the initial anti-NP365-380
line
failed to mount any primary in vitro response to A/PR/8-infected syngeneic
spleen
cells (Fig
.
6 d)
.
This inability to elicit a primary antiviral response in con-
junction
with the expansion of only substrain-specific CTL strongly suggested that
the
A/PR/8 activity shown in Fig
.
6 b was derived as a consequence of peptide priming
and
not from inadvertent influenza infection of the mice used in this study
.
The
E.G7-OVA-transfected
line could neither elicit a primary response nor could it selec-
tively
expand any transfectant-specific effector from the CTL populations derived
by
primary OVA-peptide stimulation (data not shown)
.
Furthermore, we were notJ
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FIGURE 6.
￿
Selection for A/PR/8-specific
CTL. CTL used in the assay shown in Fig.
5 c were stimulated for a further 5 d
in the presence of (a) NR;65_:i8o or (b)
30:1
￿
10:1
￿
3:1
￿
A/PR/8-infected spleen cells. Spleen cells
from (c) A/PR/8-infected or(d) uninfected
- d
￿
C57BL/6 mice were stimulated for 5 d in
the presence of A/PR/8-infected spleen
cells. Specific lysis was measured on the
-
￿
following targets: (*)EL4 + l0pg/ml
NP_ie5_.iso, (")A/PR/8-infected EL4, (0)
A/HK/68-infected EL4, or (O)EL4 alone.
able to select a population of CTL capable oflysing A/PR/8-infected EL4 cellsfrom
the OVA digest-specific CTL lines.
Discussion
The major finding of our work is that peptides can elicit strong, MHC-restricted
CTL responses measurable after 5 d of culturewith spleen cells from unprimed mice.
Conventional presentation of MHC-restricted antigens, such as by virus-infected
or minor histocompatibility-disparate cells, does not result in measurable primary
in vitro responses. This wasevidentby the failure ofinfluenza A/PR/8-infected cells
to induce aprimary response (Fig. 6 d). Previously, only MHC-different stimulators
(25-27) or hapten-modified syngeneic cells (28, 29) have been reported to give vig-
orous primary responses. The antipeptideresponses reported here are much weaker
than alloreactive responses and are very dependent on a high cell density in the cul-
tures. However, it is clear that while influenza virus-infected cells cannot stimulate
the response, one antigeneic peptide from the NP componentof thevirus can. Simi-
larly, we would predict that while it is not possible to observe a primary in vitro
CTL response of H-2b female spleen cells to the male-specific-HY antigen by stim-
ulation with male cells, if we knew the sequence ofone of the H-Y antigenic peptides
we would be able to use such a peptide to generate a response.1776
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To explain the success of exogenous peptide immunization and the failure ofen-
dogenous peptide presentation in vitro, we invoke the determinant density argu-
ment. It has been argued previously that the strong response to MHC allogeneic
cells is due to the high density of MHC determinants (15, 16). It is possible that
an analogous situation pertains as aconsequence ofthe exogenous addition ofpep-
tides at high concentrations. Under these circumstances it may be that a large frac-
tion ofMHC molecules are occupied by the added peptide, while in the case ofen-
dogenous protein synthesis the analogous peptide would occupy a much smaller
fraction ofthe MHC molecules. With a higher surface density ofa particular pep-
tide/MHC complex we would expect T cells with lower receptor affinity to be able
to respond. Thus, the bulkofantipeptide CTL maybe unable tolyse cells expressing
endogenous determinants. This is exactly what was observed for anti-NP365-380
CTL; the majority ofeffectorsfailed tolyseA/PR/8-infected targets (Fig. 5 c). Within
this population there existed a small proportion ofCTL with high receptor affinity,
and these were selectively expanded by stimulating with the A/PR/8-infected spleen
cells (Fig. 6 b).
In contrast to the anti-NP365-380 CTL, no corresponding E.G7-OVA-reactive
CTL were detected within the anti-CN OVA or anti-T OVA populations. We at-
tribute this to differences between the OVA peptides and the NP365-380 peptide
related to antigen processing. The nucleoprotein peptide mimics the endogenous
CTL determinant derived by the cellular degradation ofthe A/PR/8 nucleoprotein.
It is possible that the OVA peptides used for in vitro priming, such as OVA111-122,
are not produced as a consequence ofcellular processing ofthe OVA gene product.
Consistent with this suggestion, CTL derived by direct stimulation with OVAI1I-122-
containing digest would then fail to lyse E.G7-OVA since it does not express the ap-
propriate determinant (Fig. 5 b). Furthermore, we have observed that in vivo im-
munization with E.G7-OVA elicits OVA-specific CTL that fail to lyse targets in the
presence of OVAIll-122 (Moore, M. W., M. J. Bevan, and E R. Carbone, manu-
script in preparation).
It is likely that our success in eliciting a class I-restricted CTL response is due
in part to the direct association of degraded antigen with the MHC products. This
may have obviated the need for any form ofcellular processing. Antigen processing
combined with intracellular trafficking are thought to be the essential mechanisms
that discriminate between class I- and class II-restricted antigen presentation (10,
11). The two processing pathways are thought to be distinct. Native, exogenous pro-
teins are endocytosed and degraded within the endosomalcompartment before reex-
pression on the cell surface in association with class II MHC molecules (30, 31).
In contrast, endogenous class I-restricted antigens are thought to be degraded by
an alternative mechanism (32, 33). Thus, native OVA, which must be degraded for
antigen presentation, failed to elicit primary effectors in vitro and was incapable
of sensitizing targets for lysis by peptide-specific CTL. Recently, Staerz et al. (34)
have disputed the suggestion that class I and class II antigen presentation represent
separate pathways. Theyhave claimed that native proteincan elicit peptide-specific,
class I-restricted CTL by in vivo priming. We suggest that many of their results
may be explainedon the basis ofdirect in vitro peptide stimulation rather than suc-
cessful in vivo immunization with native protein.
There maybe other features that distinguish endogenous and exogenous peptideCARBONE ET AL.
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presentation in addition to the differences in processing requirements and cell sur-
face densities discussed above. For example, the broad MHC haplotype crossreac-
tivity noted for the in vitro-induced anti-CN OVA CTL (Fig. 4 a) may represent
a unique association of peptide with class I protein at sites that are not accessible
to endogenous peptide determinants. Such sites may exist at monomorphic regions
of the K-, D-, or L-encoded proteins or on the proteins encoded by the relatively
conserved Qa/Tla genes. However, despite all these differences, it is clearthat exoge-
nous peptides can effectively substitute for conventional CTL determinants, such
as viral antigens, both fortarget sensitization (7, 9) and forCTL priming, as demon-
strated here for NP365-380.
The abilityto elicit CTL by peptide stimulation affordsus arelatively simple tech-
nique with which to study class I-restricted T cell recognition. Since T cells are
specific for denatured rather than native forms of foreign antigens, peptides clearly
represent apotential means ofeffectivevaccination. In the particular case of influenza,
specific CTL populations (35) and clones (36, 37)have proven effective in protecting
naive individuals against lethal influenza infection. It maybe ofinterest to ascertain
whetherthe virus-reactive CTL derived from in vitro peptide priming can also pro-
vide the same protection in vivo. Ifthat is thecase, then primary in vitro CTL stim-
ulation could provide us with information that will prove useful in the design of
efficient antiviral vaccines.
Summary
Antigen-specific cytotoxic T cells can be generated by primary in vitro stimula-
tion of spleen cells from C57BL/6 mice with appropriate peptide fragments. This
response can be elicited without prior in vivo immunization . Chicken OVA frag-
mented with either cyanogen bromide (CN OVA) or trypsin (T OVA) was used as
a source of mixed peptides. A synthetic peptide, NP365-380, representing the se-
quence 365-380 from influenza virus A/PR/8 nucleoprotein, was also used, since
this contains the main determinants recognized by CTL generated from H-2b mice
infected with A/PR/8 virus. Theprimaryin vitro cytotoxic Tcell response waspep-
tide specific, since targets were lysed only in the presence of appropriate peptide
antigens. Native OVAcouldnot elicit primary effectors in vitronorcouldit sensitize
targets forlysis by OVA digest-specific CTL. A synthetic peptide corresponding to
residues 111-122 within the OVA sequence could sensitize targets forlysis by effectors
induced against T OVA.
Effectors generated by in vitro stimulation were CD8+ , CD4- , and H-2Db-
restricted for NP365-38o and T OVA recognition. CN OVA-specific effectors were also
CD8`, CD4- , but surprisingly, were able to lyse a range of H-2-different targets
in an antigen-specific manner. These effectors failed to lyse a tumor line that does
not express class I MHC molecules. This broad MHC restriction pattern was also
apparent at the clonal level.
In all cases, the antipeptide CTL generated by primary in vitro stimulation were
inefficient in lysing target cells expressing endogenous forms of antigens, such as
influenza virus-infected cells or cells transfected with the OVA cDNA. However,
cytotoxic T cell lines generated in vitro against the NP365-380 peptide did contain
a minorpopulation ofvirus-reactive cells that could be selectively expanded by stim-
ulation with A/PR/8-infected spleen cells. These results are discussed in terms of1778
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class I-restricted T cell stimulation in the absence of antigen processing by high
surface densities of peptide/MHC complexes .
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